Second phase II trial of razuprotafib to prevent and treat the severe respiratory distress in COVID-19 patients
Latest Information Update: 13 Jul 2022
At a glance
- Drugs Razuprotafib (Primary)
- Indications COVID 2019 infections; Respiratory distress syndrome
- Focus Therapeutic Use
- Sponsors Aadi Bioscience; Aerpio Pharmaceuticals
- 12 Aug 2020 According to an Aerpio Pharmaceuticals media release, trial start up activities are progressing rapidly.
- 06 Aug 2020 New trial record
- 04 Aug 2020 According to an Aerpio Pharmaceuticals media release, the company in partnership with Medical Technology Enterprise Consortium, will initiate second COVID-19 trial. MTEC will provide up to $5.1 million in funding toward the clinical trial. Aerpio will support the trial with in kind spending in the amount of $2.8 million.